Session

IBD (Posters)

IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY
IMPROVEMENT OF QUALITY OF LIFE AND CONTINENCE IN PATIENTS WITH DISTAL ULCERATIVE COLITIS TREATED BY MESALAZINE. QUARTZ STUDY

IBD (Posters)  et al.

INFLIXIMAB RESPONSE IN INFLAMMATORY BOWEL DISEASES IS LINKED TO INTERACTION BETWEEN MUCOSAL MICROBIOTA COMPOSITION AND HOST GENE-EXPRESSION
INFLIXIMAB RESPONSE IN INFLAMMATORY BOWEL DISEASES IS LINKED TO INTERACTION BETWEEN MUCOSAL MICROBIOTA COMPOSITION AND HOST GENE-EXPRESSION

IBD (Posters)  et al.

INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN INDIVIDUALS WITH HIV IN BOTH DANISH AND US COHORTS
INCREASED RISK OF INFLAMMATORY BOWEL DISEASE IN INDIVIDUALS WITH HIV IN BOTH DANISH AND US COHORTS

IBD (Posters)  et al.

COMPLICATIONS AND ADVERSE EFFECTS RELATED TO SURGICAL AND MEDICAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVELY RECRUITED POPULATION-BASED COHORT
COMPLICATIONS AND ADVERSE EFFECTS RELATED TO SURGICAL AND MEDICAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVELY RECRUITED POPULATION-BASED COHORT

IBD (Posters)  et al.

TREATMENT AND OUTCOME OF ULCERATIVE COLITIS DURING THE FIRST 10 YEARS AFTER DIAGNOSIS IN A PROSPECTIVELY FOLLOWED POPULATION-BASED COHORT
TREATMENT AND OUTCOME OF ULCERATIVE COLITIS DURING THE FIRST 10 YEARS AFTER DIAGNOSIS IN A PROSPECTIVELY FOLLOWED POPULATION-BASED COHORT

IBD (Posters)  et al.

NEW DIAGNOSTIC CAPABILITIES FOR CROHN´S DISEASE: USE OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM
NEW DIAGNOSTIC CAPABILITIES FOR CROHN´S DISEASE: USE OF FATTY ACID PROFILES OF ERYTHROCYTE MEMBRANES AND BLOOD SERUM

IBD (Posters)  et al.

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS
ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS
EFFICACY AND SAFETY OF TOFACITINIB RETREATMENT FOR ULCERATIVE COLITIS AFTER TREATMENT INTERRUPTION: AN UPDATE OF RESULTS FROM THE OCTAVE CLINICAL TRIALS

IBD (Posters)  et al.

UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY
UPDATE ON LABORATORY PARAMETERS RELATED TO MONITORING IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE OCTAVE OPEN-LABEL, LONG-TERM EXTENSION STUDY

IBD (Posters)  et al.

SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
SERUM LIPID AND C-REACTIVE PROTEIN LEVELS BY TREATMENT RESPONSE FOLLOWING 8 WEEKS OF TOFACITINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

IBD (Posters)  et al.

CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019
CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS PROGRAMME: AN UPDATE AS OF MAY 2019

IBD (Posters)  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 6.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

IBD (Posters)  et al.

PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020
PREGNANCY OUTCOMES IN THE TOFACITINIB ULCERATIVE COLITIS OCTAVE STUDIES: AN UPDATE AS OF FEBRUARY 2020

IBD (Posters)  et al.

HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019
HERPES ZOSTER INFECTION IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING TOFACITINIB: AN UPDATE AS OF MAY 2019

IBD (Posters)  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATED ANALYSIS OF INFECTION RATES IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME

IBD (Posters)  et al.

PROACTIVE THERAPEUTIC DRUG MONITORING IN THE EARLY PHASE OF INFLIXIMAB THERAPY: RESULTS FROM A 30 WEEK MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS (THE NOR-DRUM STUDY)
PROACTIVE THERAPEUTIC DRUG MONITORING IN THE EARLY PHASE OF INFLIXIMAB THERAPY: RESULTS FROM A 30 WEEK MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS (THE NOR-DRUM STUDY)

IBD (Posters)  et al.

AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
AN UPDATE ON THE ANALYSIS OF NON-MELANOMA SKIN CANCER IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

IBD (Posters)  et al.

ESCHERICHIA COLI GENOTYPES AND BACTERIOCIN PRODUCTION IN THE LARGE BOWEL MUCOSA OF CROHN´S DISEASE AND ULCERATIVE COLITIS
ESCHERICHIA COLI GENOTYPES AND BACTERIOCIN PRODUCTION IN THE LARGE BOWEL MUCOSA OF CROHN´S DISEASE AND ULCERATIVE COLITIS

IBD (Posters)  et al.

SCREENING FOR IRON-DEFICIENCY IN NON-ANEMIC PATIENTS WITH IBD: DOES IT MATTER?
SCREENING FOR IRON-DEFICIENCY IN NON-ANEMIC PATIENTS WITH IBD: DOES IT MATTER?

IBD (Posters)  et al.

IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV
IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV

IBD (Posters)  et al.

Item 281 - 300 / 558
1 2 3 4 5 6 7 8 9 10 11 12 13 14
15
16 17 18 19 20 21 22 23 24 25 26 27 28